



Published in final edited form as:

Metallomics. 2015 December ; 7(12): 1541–1554. doi:10.1039/c5mt00170f.

Iron and Zinc Exploitation during Bacterial Pathogenesis

Li Ma^{1,2}, Austen Terwilliger^{1,2}, and Anthony W. Maresso^{1,3}

¹Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77459

Abstract

Ancient bacteria originated from metal-rich environments. Billions of years of evolution directed these tiny single cell creatures to exploit the versatile properties of metals in catalyzing chemical reactions and biological responses. The result is an entire metallome of proteins that use metal co-factors to facilitate key cellular process that range from the production of energy to the replication of DNA. Two key metals in this regard are iron and zinc, both abundant on Earth but not readily accessible in a human host. Instead, pathogenic bacteria must employ clever ways to acquire these metals. In this review we describe the many elegant ways these bacteria mine, regulate, and craft the use of two key metals (iron and zinc) to build a virulence arsenal that challenges even the most sophisticated immune response.

Keywords

metal; iron; zinc; pathogenesis; heme; transporters; regulation

The resting state of iron and zinc in the host

Bacterial pathogens must procure essential metals when they invade their mammalian hosts, but metal distribution within the host varies due to their respective chemistries and biological functions. Iron and zinc, the 2nd and 27th most abundant metals in the earth's crust, respectively^{1,2}, are essential nutrients for virtually all living organisms^{3,4}. Iron primarily exists as two cations, the oxidized ferric (Fe³⁺) form and the reduced ferrous (Fe²⁺) form⁵. The gain or loss of an electron from these ions is required for multiple important biological functions, such as oxygen carrying by hemoglobin, electron transport chain reactions, and DNA biosynthesis^{6,7}. Zinc exists solely as Zn²⁺ and as such is unable to perform redox reactions⁸. Consequentially, organisms take advantage of these functional differences between iron and zinc to use the metals in distinctly different biological processes. Because oxygen is a major component of the air, we live in an oxidative environment, and as such the oxidized form of iron (i.e. Fe³⁺) is the most stable and dominant form (e.g. rust)^{5,9}. However, this ferric form of iron is insoluble under common aerobic conditions. Thus, the incorporation of iron into biological structures can be challenging. In contrast, the ferrous

³To whom correspondence should be addressed.

²Contributed equally

form of iron (Fe^{2+}) is relatively soluble under aerobic conditions and is found in most natural water sources^{5,9}.

Although iron makes up less than 0.01% of human body weight (2-4 grams)¹⁰, it is absolutely necessary for strong bones and oxygen binding to hemoglobin and myoglobin^{6,11}. Zinc similarly comprises 2-3 grams of human body weight, which is distributed primarily in skeletal muscle and bone¹². Zinc is found throughout the body and is redistributed from the blood to the liver during pathology, an action that presumably recycles this metal¹³. Both metals are intertwined with the host's immune system. The status of zinc affects important functions of host immunity, including lymphocyte production and function, monocyte recruitment, and cytokine production¹⁴⁻¹⁷. Iron is used to catalyze the formation of reactive oxygen species (ROS) during macrophage-based killing of bacteria¹⁸. A dedicated organelle, the phagolysosome, uses the ability of iron to cycle in Fenton reactions and generate ROS, which harms bacterial membranes, proteins, and DNA¹⁹. A description of common host and bacterial factors involved in the exploitation of metals is shown in Table 1. Trafficking of iron and zinc inside of the mammalian host remains parallel to each other. Iron is mainly absorbed from the diet in the duodenum and upper jejunum, in the forms of heme (e.g. meat) or non-heme (e.g. plant), both of which are fractionally absorbed (in the case of iron)^{20,21}. The majority of dietary zinc comes from red meat, poultry, and seafood²². Zinc is absorbed throughout the intestinal tract facilitated by membrane ZnT and Zrt-, Irt-like protein ZIP transporters as well as cysteine rich intestinal protein (CRIP)^{23,24}. DMT1 (divalent metal transporter 1) and HCP1 (heme carrier protein 1) are responsible for iron and heme absorption, respectively, in the duodenum^{25,26}. The majority of iron that pathogens encounter (~75% of host iron) will be used as a heme cofactor incorporated into hemoglobin (e.g. during erythropoiesis) which coordinates oxygen for its delivery to tissues and cells^{25,27,28}. Zinc, on the other hand, is more broadly used. This metal is incorporated into about 10% of human proteins, of which over 300 enzymes require Zn^{2+} for metabolic and regulatory functions^{2,4,29}. An invading pathogen will find 90% of host zinc in skeletal muscle and bone, with some present in organs like the spleen, liver, and kidneys^{12,30}. In these tissues and circulating cells, host zinc is present at 100-500 μM concentrations intracellularly, a large portion of which is bound to metallothioneins^{31,32}. Intracellular zinc is further compartmentalized within the cytosol (50%), nucleus (30-40%), and membranes^{2,33}. Like iron, the remaining zinc, about 0.1%, is present in blood serum (1.25 $\mu\text{g}/\text{ml}$ serum) bound to albumin (73-91%), macroglobin (9-27%), or various serum proteins and amino acids (2-8%)³⁴⁻³⁶. Iron and zinc are of such critical importance that their loss must quickly be replenished. For example, humans lose iron daily through sweating, shedding of surface cells, and gastrointestinal blood loss, making dietary replenishment of iron a necessary activity³⁷. Too little iron results in anemia and is the most common and widespread nutritional disorder in the world²¹. The physiological importance of zinc to humans was first described in 1963, and today zinc deficiency is a global health concern – thought to affect prenatal development, childhood growth, and infection susceptibility³⁸⁻⁴¹. Organisms must have ways to regulate metal concentrations however, since excessive levels are toxic. Excess iron can result in iron overload or haemochromatosis^{25,42}, a case of iron toxicity that damages organs because iron catalyzes Fenton reactions which generate damaging and toxic ROS⁴³⁻⁴⁶. Haemochromatosis also fosters a more beneficial

environment for invasive and opportunistic pathogens⁴⁷. Unlike iron that has two stable oxidation states (Fe^{2+} and Fe^{3+}), zinc only has one stable oxidation state (Zn^{2+}), and thus cannot directly induce generation of ROS. However, excess zinc facilitates ROS formation in neuronal cells, an effect caused by mitochondrial zinc transport and subsequent disruption of the mitochondrial membrane^{48–50}. Zinc toxicity can lead to nausea, vomiting, and diarrhea in humans, which is associated with the suppression of copper absorption and alteration of lipoprotein profiles^{51,52}.

The sequestration of iron and zinc by the host

Frustratingly for the pathogen, they cannot directly access the host reserves of iron and zinc, as their availability is very low due to nutritional immunity. Nutritional immunity is the term given to the host's ability to restrict bacterial access to critical nutrients upon an infection, during which metals such as iron and zinc are heavily sequestered by high affinity binding proteins or kept in organelles that are not accessible to bacteria⁵³. In addition, these metals are strongly associated with cellular components (such as iron in hemoglobin and ferritin and zinc bound to proteins, nucleic acids, and membranes) and therefore are not readily available unless the cell is in a diseased state². Free zinc levels of mammalian hosts have been measured in the picomolar range for cytosol and plasma – while that of iron is 10^{-24} M in mammalian blood^{54–56} – although micromolar concentrations of zinc can be present in airway epithelia and mucosal membranes⁵⁷.

Mining the metals a bacterium needs to replicate, grow, and survive is challenging, and mammals use a variety of tactics to keep iron and zinc away from bacterial pathogens. Some of these mechanisms include the global regulation of metal homeostasis on a systemic basis. This includes the production of the hormone hepcidin, the host master iron balance regulator^{58,59}. Elevated levels of hepcidin leads to degradation of ferroportin, the only known cellular iron exporter in vertebrates that facilitates the release of iron to the circulatory system^{25,26,60}. Hepcidin also induces a decrease in the expression of proteins regulated by the IRE/IRP (IRE: iron response element, IRP: iron response proteins) system, including duodenal iron absorption proteins and HCP1^{25,26,60}. Similarly, global regulation of zinc storage is mediated by hormones. Glucagon and epinephrine increase metallothionein expression and zinc storage in liver tissue⁶¹. Likewise, detection of bacterial invaders via LPS can induce IL-6 expression which in turn increases metallothionein expression and reduces free zinc concentrations^{62,63}. Conversely, glucocorticoid signaling can induce zinc secretion from pancreatic cells⁶⁴.

Other mechanisms of regulation use secreted or circulating factors that keep metals sequestered. This includes transferrin and NGAL (neutrophil gelatinase-associated lipocalin). The blood protein transferrin sequesters free iron in the circulatory system such that only the peripheral cells expressing the cognate transferrin-iron receptors can transport the transferrin-bound iron⁶⁵. There is evidence that bacteria commonly target host transferrin, as it is undergoing rapid evolution to avoid recognition by bacterial pathogens⁶⁶. However, transferrin is not the only molecule with iron sequestering properties, as NGAL binds ferric-siderophore complexes^{67,68}. Siderophores are small, high affinity ferric iron binding molecules synthesized by bacteria that constitute an important cog of bacterial iron

uptake⁶⁹. Siderophore-NGAL binding further increases proinflammatory cytokine (e.g. IL6) production, likewise increasing stimulation of the host immune responses⁷⁰. The main host-secreted zinc chelation protein is calprotectin. This protein is secreted by neutrophils at the site of infection and binds zinc and manganese to limit their availability to the pathogen⁷¹. Indeed, calprotectin is found in zinc depleted abscesses of *S. aureus* and can limit other forms of microbial growth *in vitro*^{72,73}. Overall, the net effect of the above host actions during inflammation is that the amount of free metals in the circulatory system and tissue remains very low, keeping iron and zinc out of the hands of pathogenic bacteria⁷⁴. Moreover, the alteration of the cellular iron and zinc availability may have other consequences including lymphocyte proliferation and activation^{75–77}.

The bacterial acquisition of metals from the host

Facing the obstacles posed by nutritional immunity, a successful bacterial pathogen must develop efficient strategies to acquire metals from various host resources to facilitate their infection, survival, and replication. Because of the importance of these metals to the host as well, such resources are seemingly plentiful. The challenge, however, is to usurp the multiple ways the host limits access to these resources which include transferrin/lactoferrin, heme, and iron storage proteins (e.g. ferritin) as shown in Figure 1. They also include the zinc storage protein metallothionein and the zinc chelation protein calprotectin, along with zinc-associated proteins like serum albumin, alpha-2 macroglobulin, metalloproteases, and zinc-finger regulatory proteins. Here, we discuss known strategies pathogenic bacteria use to raid host resources by mining these metals.

Transferring iron from transferrin

Transferrin, the blood plasma glycoprotein that preferentially binds ferric iron, is the primary tool for delivering absorbed iron to cells. Lactoferrins are proteins of the transferrin family and are found in various secretory fluids (e.g. milk and tears)⁵⁸. In pathogenic *Neisseria* species, the outer membrane anchored protein TbpB (Transferrin-binding protein B) binds and transfers holo-transferrin to the outer membrane receptor TbpA, where iron is extracted and shuttled across the outer membrane⁷⁸. Resembling the Fe-Ent transport system in non-pathogenic *E. coli*⁷⁹, TbpA-mediated iron uptake requires the TonB-ExbB-ExbD complex to transduce energy and allow a conformational change in the N-terminal plug domain, dislodging it from the channel and allowing iron to pass through where it is picked up by the periplasmic protein FbpA (Ferric binding protein component A)⁷⁸. Finally, FbpA shuttles the iron to the inner membrane ABC transporter FbpBC that transports iron into the cytoplasm, and this process is influenced by periplasmic anion content^{78,80}. In a similar way, the outer membrane proteins LbpAB (lactoferrin binding protein AB) are involved in ferric-lactoferrin complex uptake in pathogenic *Neisseria* species^{81,82}. *Haemophilus influenzae* also contains a homolog of TbpA and is able to remove iron from host transferrin⁸³. For *Mycobacterium tuberculosis*, the iron from the holo-transferrin can be either extracted by its siderophore carboxymycobactin, subsequently transported in via a mycobactin-dependent or mycobactin-independent pathway, or holo-transferrin itself can be internalized involving GAPDH and other surface proteins⁸⁴. Thus, although transferrin is a major component of

nutritional immunity, and exhibits growth restrictive properties, pathogenic bacteria have also evolved transport systems to target transferrin as an iron source⁸⁵.

Mining heme iron

Heme and heme-containing proteins account for the most abundant source of iron in the host. Not surprisingly, bacterial pathogens have developed various strategies to mine iron from this resource. There are several mechanisms by which bacteria gain access to host heme⁸⁶. Free heme is recognized by TonB-dependent outer membrane receptors in gram negative bacteria or cell wall anchored receptors in gram positive bacteria⁸⁶. Free heme is also recognized and bound by secreted bacterial proteins named hemophores that have high affinity for the heme moiety and are made by both gram positive and gram negative bacteria⁸⁷. Hemophores also actively extract heme from heme-containing proteins^{88,89}, utilizing specific residues in the heme binding pocket to promote the loss of heme from hemoglobin⁹⁰. Additionally, the hemophores may stimulate the dissociation of hemoglobin tetramers into dimers and monomers, which have a lower affinity for the heme and increase its loss from the globin⁹¹. The hemophores have a higher affinity for heme, which will be bound at equilibrium. Once bound, the heme can be transferred to cognate surface receptors where it is then moved across the cell wall or membrane into the cytoplasm, where heme can be degraded to liberate iron⁸⁹. For example in *Bacillus anthracis*, the causative agent of anthrax, the surface anchored proteins IsdC (Isd: iron-regulated surface determinant), Hal (heme-acquisition leucine-rich repeat protein), and possibly BslK (*Bacillus* surface layer protein K) are involved in scavenging the heme moiety from heme containing proteins^{92–94}. *B. anthracis* also secretes two hemophores IsdX1 and IsdX2, which extract heme from host heme containing proteins and shuttle them to receptors in the bacterial envelope⁹⁵. Both the receptors and the hemophores use the NEAT (N-terminal near-iron transporter) domains to interact with the heme moiety through a highly conserved YXXXY motif⁹⁶. It is interesting to note that, Hbp2 (heme/hemoglobin-binding protein 2), a NEAT-domain containing hemophore in *Listeria monocytogenes*, can scavenge heme but its activity is dependent on a non-canonical tyrosine residue, suggesting an unprecedented mechanism of heme binding by this protein⁹⁷. The NEAT domain has been recognized as being very important in gram-positive biology. In addition to important roles in making bacteria more virulent⁹³, they also may serve as recombinant vaccine candidates for pathogens such as *Staphylococcus aureus*^{98,99} and *B. anthracis* (Balderas and Maresso, unpublished data). In gram negatives, HasA (heme acquisition system component A) represents a family of highly conserved hemophores identified in *Serratia marcescens*, *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Yersinia pestis*, and *Yersinia enterocolitica*⁸⁷. HasA is secreted via the type I secretion pathway and may capture heme from hemoglobin. The TonB-dependent outer membrane receptor HasR interacts with HasA to facilitate heme transfer and uptake⁸⁷.

Prospecting for ferritin iron

Ferritins are tightly regulated storage proteins that deposit and release iron to maintain its safe level within the host¹⁰⁰. Normally, ferritins are cytosolic and their extracellular concentrations are very low (<0.01% of the extracellular transferrin)¹⁰¹. In sputum and bronchoalveolar lavage fluid, there are higher levels of ferritin, which increases during diseased states (e.g. cystic fibrosis patients)¹⁰¹. Not surprisingly, lung pathogens possess the

ability to take advantage of this iron source. For example, *P. aeruginosa* secretes extracellular proteases that lyse the ferritin and release its stored ferric iron, which are reduced by secreted bacterial molecules (e.g. pyocyanin) and possibly get transported in via the Feo iron transport system¹⁰¹. Similarly, another lung pathogen, Burkholderia cenocepacia, *can use ferritin as an iron source in a protease-dependent manner*¹⁰². Bacillus cereus *also uses ferritin as an iron source. In this pathogen, the surface protein IIsA (iron-regulated leucine rich surface protein type A) recognizes and binds ferritins, leading to the destabilization and subsequently release of ferric iron ions, which are chelated by the bacterial siderophore bacillibactin and transported via the cognate membrane transporter FeuABC (ferric bacillibactin uptake protein components ABC)*¹⁰³. Thus, it appears that when labile iron in circulation is not available, bacteria can prospect into deep host reserves such as ferritin to satisfy their requirement for this metal.

Bacterial countermeasures to overcome host iron sequestration

Some pathogenic bacteria can chemically modify their secreted siderophores to evade recognition by host siderophore-binding proteins like NGAL. For example, *Salmonella* species, uro- and avian pathogenic *E. coli* strains, and certain *Klebsiella* strains (e.g. *K. pneumonia*) are able to synthesize variations of the catecholate siderophore Ent that is glycosylated¹⁰⁴. The glycosylation benefits these bacterial pathogens and contributes to virulence by interfering with NGAL binding through steric hindrance of the added bulky glucose groups^{104–106}. *Yersinia* species, some *E. coli* and *K. pneumoniae* strains are able to synthesize a structurally different siderophore termed yersiniabactin (a mixed ligands siderophore). The uptake of yersiniabactin depends on the TonB-dependent outer membrane receptor FyuA and its importance for bacterial virulence was demonstrated in *Y. enterocolitica*, *E. coli* and *K. pneumonia* but not in *Y. pestis*^{107–110}. Strains of *E. coli*, *S. flexneri*, and *K. pneumonia* produce the hydroxamate siderophore aerobactin, whose role in pathogenesis is important in some cases but dispensable in others^{111–114}. Another way to fine tune the siderophore based iron uptake system in bacterial pathogens is to “amplify” its iron uptake ability. An example is the asymptomatic bacteriuria caused by *E. coli* strain 83972. When compared to its commensal counterpart, it has additional abilities to synthesize and transport in salmochelin, aerobactin, and yersiniabactin¹⁰⁶. The redundancy of the iron transport systems contributes significantly to its colonization in the urinary tract¹⁰⁶. This feature gives the pathogen the versatility to satisfy its iron needs in different environmental niches.

Deep prospecting: iron uptake by intracellular bacteria

Nutrient levels in the extracellular milieu are under tight control by the host. The intracellular environment, however, is very nutrient rich with higher concentrations of several growth-promoting factors. The intracellular environment offers additional benefits for bacteria in that there is a low level of antimicrobial peptides, antibiotics, and humoral antibodies. But entry into host cells comes at great risk for bacteria; eukaryotic cells have intracellular sensors that activate alarms if bacterial components are detected¹¹⁵. In addition, cells contain specialized organelles called phagolysosomes that harness the harmful effects of low pH and/or reactive oxygen species to kill bacteria¹¹⁶. However, some bacteria are ideally adapted to survive and replicate in this environment, which confers a selective

needed to import iron. The basic principles of bacterial iron transport also hold true for zinc. Similar to bacteria employing Fur to regulate intracellular iron levels, they rely on Zur (zinc uptake regulator), which is a Fur family homolog protein, to regulate Zn²⁺ uptake mechanisms. Interestingly, *E. coli* derived Fur binds zinc to form active dimers, but this zinc binding activity is not necessary for Fur mediated regulation in other bacteria^{137,138}. This evidence suggests possible crosstalk between iron and zinc homeostasis mechanisms. Upon binding Zn²⁺, Zur proteins actively bind to DNA and suppress transcription of downstream genes associated with zinc import, like the ABC transporters¹³⁹. This negative feedback loop prevents the toxic buildup of intracellular zinc and induces expression of zinc acquisition mechanisms when the metal is limiting. Bacteria might also import zinc into the cytosol with ZIP transporters; however, they are only known to be present in *E. coli*^{140,141}. While their presence is generally necessary for full virulence, it is unclear whether these transporters alone are sufficient to maintain an infection, or if like iron, some liberation of zinc from host protein and cellular stores is also required. Finally, some non-specific transporters can import both metals. This is true of ZupT (Zinc uptake protein component T), which in addition to transporting zinc can also transport ferrous iron¹⁴¹.

The use of metals to power bacterial virulence

Bacteria use the metals they acquire to drive key cellular processes, some of which were briefly mentioned above. These activities are necessary for growth and replication of the microbe, which in turn sustains and propagates the infection. What sometimes is lost in this consideration is that acquired metals are important catalysts for two broadly conserved and critically important types of bacterial hydrolases that directly interface with the host and/or the host response to infection. Examples include the production of metalloproteases and lactamases that require zinc for their catalytic activity. It is becoming increasingly clear that, much like iron, zinc is essential to the survival of a pathogen during host infection, but perhaps in a different way. Whereas iron serves as a co-factor in processes related to energy transduction through respiration, zinc can be crafted into factors that interact with the host on several levels. In the final part of this review, we consider the importance of metals in the use of bacterial weapons of warfare – the very virulence factors bacteria use to overcome the host barriers to infection.

Proteases are enzymes that hydrolyze peptide bonds in proteins or peptides. They can be exoproteases – which cleave at the amino or carboxy terminus of proteins, or endoproteases – which are capable of cleaving at one or multiple sites within a protein. Proteases are categorized by the catalytic residue in their active site. This includes aspartic, threonine, serine, and cysteine proteases, with these residues driving catalysis. For a comprehensive review on the classes and activities of the multitude of known proteases, please see references^{142–144}. A critical feature of many proteases is that one or more metals serve as a co-factor for catalysis, the so-called metalloproteases. Most bacterial metalloproteases are secreted and use zinc as the metal cofactor. Zinc metalloproteases contain variations on the typical HEXXH binding motif, which coordinates a single Zn²⁺ ion with three amino acids, usually histidine and glutamate, but sometimes aspartate and cysteine residues. The catalytic cleft is composed of a tridentate site with a coordinated water molecule^{145,146}. Mechanistically, zinc metalloproteases cleave peptide bonds via nucleophilic attack on the

carbonyl carbon in the peptide – an action performed by the deprotonized water molecule. During the transition state, zinc helps to stabilize the negatively charged intermediate product. The final products exit the catalytic site upon hydrolysis by the water molecule and creation of amine and carboxyl termini on the new peptide fragments¹⁴⁷. Metalloproteases typically exhibit broad specificity, as has been described for vEP of *Vibrio fulnificus*, InhA1 of *Bacillus anthracis*, and ZmpB of *Burkholderia cenocepacia*^{148–150}. The broad specificity of bacterial metalloproteases may actually suit the pathogen's needs by facilitating the disruption of physiologically important host processes, including the breakdown of barriers, the destruction of key signaling intermediates, and the release of nutrients such as metals from host metalloproteins. For example, collagen is the main component of skin, tendons, and cartilage. It is a fibrous, structural protein that is present in connective tissues and comprises 25–33% of all proteins in mammals. It is also a common target of zinc metalloproteases, resulting in compromised host barriers that spread infection and delay immune clearance¹⁵¹. Some examples of collagenolytic proteases are *B. anthracis* Npr599 and InhA1, both of which cleave collagen types I and IV *in vitro*¹⁴⁹, and the *Burkholderia cenocepacia* metalloproteases ZmpB and ZmpA^{150,152}. Tissue disruption can also occur by cleavage of tight cell junctions. Zona occluden-1 is a tight junctional protein which is cleaved by *Pseudomonas aeruginosa* pseudolysin, *Vibrio cholera* hemagglutinin, and *B. anthracis* InhA1; the latter thought to cause increased blood brain barrier permeability and dissemination of bacilli^{153–155}. Immune components can also be directly cleaved by metalloproteases. This is true for the IgA protease of *Streptococcus sanguis* and the immunoglobulin protease of *S. marcescens*^{156,157}. This also includes mirabilysin of *Proteus mirabilis* and pseudolysin of *P. aeruginosa* which both cleave IgG^{158,159}. Interestingly, the host is thought to directly target the zinc status of bacteria in infected tissues as a nutritional immunity strategy. Specifically, neutrophils that are recruited to infection sites secrete the metal chelator protein calprotectin, which mainly binds zinc and manganese. As stated above, calprotectin is found in zinc-depleted *S. aureus* abscesses, and it can reduce other forms of microbial growth *in vitro*^{72,160,161}. It may be that the chelation of zinc by the host has a direct effect of preventing bacterial metalloproteases from acquiring this critical metal co-factor.

Metalloproteases can also interfere with immune clearance by interfering with signaling cascades. Lethal toxin from *B. anthracis* induces endothelial disruption by cleaving MAP kinases¹⁶². InhA1 can also cleave prothrombin and factor X to induce clotting¹⁶³. Similarly, fibrinogen is cleaved by *Serratia marcescens* to interfere with the extracellular matrix and coagulation cascade¹⁵⁷. Cytokines or interleukins (IL) are the recruitment signal for neutrophils and macrophages, and they can also be disrupted by pathogenic bacteria to avoid immune clearance. Examples include the cleavage of IL-2 by *Legionella pneumophila* metalloprotease, and cleavage of the IL-6 receptor by supernatants of *S. marcescens* and other bacteria^{164,165}. An overview of zinc metalloprotease virulence mechanisms and their host substrates is shown in Figure 2. The broad use of such metals in mechanisms like these further supports the notion that blocking the ways bacteria attain these metals might serve as both an anti-infective and anti-virulence strategy.

An intriguing and understudied aspect of metalloproteases is their potential role in nutrient acquisition. Much work has been done to elucidate the amino acid acquisition systems of

intracellular pathogens. These bacteria redirect host autophagy and lysosomal degradation pathways to liberate free amino acids, a concept termed nutritional virulence^{166,167}. Extracellular proteases are known to degrade hemoglobin, transferrin, and other iron and heme containing compounds^{168–170}. Presumably these functions are dedicated to acquiring iron, but their potential role in amino acid acquisition has not yet been defined. However, it was recently discovered that *V. cholera* employs the metalloprotease VchC to help utilize collagen as its sole nutrient source¹⁷¹, and that *B. anthracis* metalloprotease InhA1 can degrade hemoglobin as an amino acid source *in vitro*¹⁷². With this information we should consider the possibility that metalloproteases and proteases in general not only interfere with host defense mechanisms, but can also release essential metals and amino acids from a distance for bacteria to scavenge.

Finally, metals like zinc are important in other bacterial processes, including the break-down of life-saving antibiotics. It is widely recognized that modern medicine is on the precipice of a microbial-induced disaster. The rise of strains (and enzymes) that are resistant to (and can inactivate) commonly used and recently developed antibiotics is risking nearly 80 years of progress in successfully treating once life-threatening bacterial infections. Much of this resistance is driven by a large class of enzymes localized to the bacterial surface termed metallo- β -lactamases. These enzymes cleave the β -lactam ring of antibiotics that include the penicillins, carbapenems, cephalosporins, and monobactams¹⁷³. Similar in mechanism to the metalloproteases, metallo- β -lactamases require zinc cations in the catalytic cleft to exert their full activity. A water molecule performs nucleophilic attack on the carbonyl carbon in the β -lactam ring while zinc stabilizes the negatively charged intermediate. This reaction breaks the β -lactam ring, which can no longer inactivate the bacterial transpeptidase that makes the cell wall¹⁷⁴. Metallo- β -lactamases are distributed across dozens of gram-positive and gram-negative species, with the most notorious in recent times being NDM-1 (first discovered in a *K. pneumoniae* strain isolated from a patient that visited New Delhi)^{174–176}. Since then, NDM-1 has been discovered in clinical isolates in the United Kingdom, Japan, Pakistan, United States, and Canada, and is found in multiple gram-negative genre like *Escherichia* and *Acinetobacter*¹⁷⁷. Despite the critical importance of such enzymes in undermining the medical miracle of antibiotics, it is not understood the sources of, or mechanism by which host zinc is incorporated into these enzymes.

Future work and perspectives

Not all bacteria are pathogens. A number of bacteria, which are now recognized as the microbiome and commonly found on or in body surfaces such as the gastrointestinal and respiratory tract, skin, and nares, often exert beneficial effects on our health^{178,179}. One commensal bacterium that lives in the human gut is *Escherichia coli*, and it utilizes several iron-uptake mechanisms to compete not only with the host but also other bacteria occupying the intestinal niche. One such mechanism is to synthesize siderophores, which are secreted into the surrounding environment. Siderophores bind free iron by virtue of their high affinity and are then imported via the cognate membrane transporters¹⁸⁰. A second mechanism commensal *E. coli* uses to attain iron is through the use of two transport systems. The ferric-citrate transport system transports in citrate¹⁸¹. Citrate is a common component of our daily diet and can be found in many foods such as green leafy vegetables and fruits and thus

found in our intestinal tract¹⁸². It also, by virtue of its structure, can weakly chelate iron and often is bound to this metal. The ferrous iron transport system shuttles in free ferrous iron¹⁸³. Due to the fact that most commensal bacteria live in the lower intestine where anaerobiosis and acidification are common and favors ferrous iron¹⁸⁴, having this system may be a benefit in this environment. Finally, bacteria of the intestinal microbiome can utilize xenosiderophores. Xenosiderophores are siderophores that demonstrate cross species and even cross kingdom activity, i.e. synthesized by one species but are able to be utilized by different species.

Bacteroides species are opportunistic pathogens and another representative of the commensal bacteria¹⁷⁹. Similar to *E. coli*, *Bacteroides* species possess the ferrous iron transport system¹⁸⁵. *B. fragilis* has a putative siderophore mediated iron transport system¹⁸⁶, but the siderophore has not yet been identified¹⁸⁷. *B. fragilis*, however, has the ability to utilize heme and hemoglobin as an iron source, a feature that is associated with it being an opportunistic pathogen and distinguishes itself from the discussion of commensals that take up metals such as the nonpathogenic strains of *E. coli*^{188,189}. Recently, one member of *Bacteroidetes* phylum demonstrated iron acquisition from transferrin, but the medical significance of this finding is not known¹⁹⁰.

In summary, although there are clear examples of commensal bacteria that inhabit the skin or GI tract and utilize a multitude of systems to attain essential metals, the fact that they are utilized for colonization of the host would suggest that they also can be perceived as virulence factors. In this context, they may not directly participate in the pathological consequences of the infection but certainly are needed to maintain a relationship with the host that may “break bad” when the host is immunocompromised.

When a bacterial pathogen infects the host, it also encounters a polymicrobial environment, and must develop ways to compete for essential nutrients such as iron and zinc with the microbiome. One strategy is to take advantage of other microbes to fulfill nutrient requirements via inter- and intraspecies metabolite usage¹⁹¹. *S. aureus* is an opportunistic pathogen mostly found in the human respiratory tract and on the skin, and represents a good example of the interspecies metabolite usage¹⁹². In the presence of *S. aureus*, *P. aeruginosa* produces a staphylolytic protease LasA, which targets the glycyl-glycine and glycyl-alanine bonds of the pentaglycine interpeptide bridge in the *S. aureus* peptidoglycan, leading to *S. aureus* lysis. The lysed *S. aureus* serves as the iron pool for *P. aeruginosa* to support its growth¹⁹³. *H. influenza* also benefits from the presence of *S. aureus* because the hemolysins (α , β , and γ) produced by *S. aureus* help lyse erythrocytes to release nutrients (e.g. heme) to facilitate *H. influenza* growth. The mixture of staphylococcal strains deficient in menaquinone biosynthesis with those lacking heme biosynthesis reaches the wild type level of growth *in vitro* and remains fully virulent when tested in a murine model of osteomyelitis¹⁹⁴. The restoration is explained by the ability of the menaquinone biosynthesis mutant to synthesize and supply heme to the population¹⁹⁴. As more investigation focuses on the ecosystem of the microbiome and its relation to human disease, the mechanisms by which interspecies nutrient exchange occurs will become more evident.

The importance of metal uptake during infections and the seemingly continuous development of resistance against antibiotics compels consideration of the inhibition of metal uptake for antibacterial drug development^{195,196}. Indeed, an increasing number of studies have evaluated the effectiveness of targeting bacterial iron metabolism as an antibacterial strategy, with efficacy demonstrated in some cases but not others^{197–201}. Additionally, the “Trojan horse” strategy shows promise, where siderophore-like molecules are loaded with toxic drugs^{196,202}. Considering the multiple roles metalloproteases display in virulence, as well as the critical requirement of metals in β -lactamase activity, there exists a need to understand how these important enzymes become loaded with zinc. Future studies should be directed towards testing the clinical validity of these ideas as well as exploring new therapeutic entry points that disrupt bacterial metal homeostasis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors offer the sincerest of apology for not being able to cite all relevant works (due to page constraints). This work was supported in part by grants AI097167 and AI116497 from the National Institutes of Health. We thank the Maresso laboratory for comments and suggestions.

References

1. Wicander, R.; Monroe, J. Essentials of geology. 4th. Cengage Learning; Boston, MA: 2005. p. 63-64.
2. Vallee B, Falchuk H. *Physiol Rev.* 1993; 73:79–118. [PubMed: 8419966]
3. Cairo G, Bernuzzi F, Recalcati S. *Genes Nutr.* 2006; 1:25–39. [PubMed: 18850218]
4. Andreini C, Banci L, Bertini I, Rosato A. *J Proteome Res.* 2006; 5:3173–3178. [PubMed: 17081069]
5. Kappler A, Straub KL. *Rev Mineral Geochemistry.* 2005; 59:85–108.
6. Winter WE, Bazydlo LA, Harris NS. *Lab Med.* 2014; 45:92–102. [PubMed: 24868988]
7. Huang M, Parker MJ, Stubbe J. *J Biol Chem.* 2014; 289:28104–28111. [PubMed: 25160629]
8. Kambe T, Tsuji T, Hashimoto A, Itsumura N. *Physiol Rev.* 2015; 95:749–784. [PubMed: 26084690]
9. Lu S, Gischkat S, Reiche M, Akob DM, Hallberg KB, Küsel K. *Appl Environ Microbiol.* 2010; 76:8174–8183. [PubMed: 20971876]
10. Aggett, P. Present Knowledge in Nutrition. 10th. Erdman, J.; Macdonald, I.; Zeisel, S., editors. Wiley-Blackwell; Washington, DC.: 2012. p. 506-20.
11. Harris MM, Houtkooper LB, Stanford VA, Parkhill C, Weber JL, Flint-Wagner H, Weiss L, Going SB, Lohman TG. *J Nutr.* 2003; 133:3598–3602. [PubMed: 14608080]
12. Wastney ME, Aamodt RL, Rumble WF, Henkin RI. *Am J Physiol.* 1986; 251:R398–408. [PubMed: 3740321]
13. Cerasi M, Ammendola S, Battistoni A. *Front Cell Infect Microbiol.* 2013; 3:108. [PubMed: 24400228]
14. Moulder K, Steward M. *Clin Exp Immunol.* 1989; 77:269–274. [PubMed: 2789119]
15. Gross R, Osdin N, Fong L, Newberne P. *Am J Clin Nutr.* 1979; 32:1260–1265. [PubMed: 312599]
16. Weston WL, Huff JC, Humbert J, Hambidge K, Neldner K, Walravens PA. *Arch Dermatol.* 1977; 113:422–5. [PubMed: 848970]
17. Nishida K, Hasegawa A, Nakae S, Oboki K, Saito H, Yamasaki S, Hirano T. *J Exp Med.* 2009; 206:1351–64. [PubMed: 19451265]

18. Klebanoff SJ, Kettle J, Rosen H, Winterbourn CC, Nauseef WM. *J Leukoc Biol.* 2013; 93:185–198. [PubMed: 23066164]
19. Slauch JM. *Mol Microbiol.* 2011; 80:580–3. [PubMed: 21375590]
20. Rhodes J, Beton D, Brown DA. *Gut.* 1968; 9:323–324. [PubMed: 5661970]
21. Food and Agriculture Organization/World Health Organization. Vitamin and mineral requirements in human nutrition: report of a joint FAO/WHO expert consultation. 2nd. 2004.
22. [May 19, 2015] Natl Institutes Heal. <http://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/>
23. Wang X, Zhou B. *IUBMB Life.* 2010; 62:176–82. [PubMed: 20120011]
24. Hempe JM, Cousins RJ. *J Nutr.* 1992; 122:89–95. [PubMed: 1729476]
25. Silva B, Faustino P. *Biochim Biophys Acta.* 2015; 1852:1347–1359. [PubMed: 25843914]
26. Przybyszewska J, ekanowska E. *Gastroenterol Rev.* 2014; 4:208–213.
27. Petersen HL, Peterson CT, Reddy MB, Hanson KB, Swain JH, Sharp RL, Alekel DL. *Int J Sport Nutr Exerc Metab.* 2006; 16:281–295. [PubMed: 16948484]
28. Chiabrando D, Mercurio S, Tolosano E. *Haematologica.* 2014; 99:973–983. [PubMed: 24881043]
29. Andreini C, Banci L, Bertini I, Rosato A. *J Proteome Res.* 2006; 5:196–201. [PubMed: 16396512]
30. Wang Y, Tang JW, Ma WQ, Feng J. *Biol Trace Elem Res.* 2010; 133:325–34. [PubMed: 19557314]
31. Plum LM, Rink L, Haase H. *Int J Environ Res Public Health.* 2010; 7:1342–1365. [PubMed: 20617034]
32. Fukada T, Yamasaki S, Nishida K, Murakami M, Hirano T. *J Biol Inorg Chem.* 2011; 16:1123–34. [PubMed: 21660546]
33. Eide DJ. *Biochim Biophys Acta.* 2006; 1763:711–22. [PubMed: 16675045]
34. Folin M, Contiero E, Vaselli GM. *Biometals.* 1994; 7:75–79. [PubMed: 8118176]
35. Foote JW, Delves HT. *J Clin Pathol.* 1984; 37:1050–1054. [PubMed: 6206098]
36. Prasad AS, Oberleas D. *J Lab Clin Med.* 1970; 76:416–25. [PubMed: 5458331]
37. Centers for Disease Control and Prevention. *Morb Mortal Wkly Rep.* 1998; 47(RR3):1.
38. Prasad S. *Am J Clin Nutr.* 1991; 53
39. Shah D, Sachdev HPS. *Br J Nutr.* 2001; 85
40. Imdad A, Bhutta ZA. *BMC Public Health.* 2011; 11(Suppl 3):S22. [PubMed: 21501440]
41. Mayo-Wilson E, Junior J, Imdad A, Dean S, Chan X, Chan E, Jaswal A, Bhutta Z. *Cochrane Database Syst Rev.* 2014; 5
42. Yun S, Vincelette ND. *Crit Rev Oncol Hematol.* 2015; 95:12–25. [PubMed: 25737209]
43. Sawada H, Hao H, Naito Y, Oboshi M, Hirotsu S, Mitsuno M, Miyamoto Y, Hirota S, Masuyama T. *Arterioscler Thromb Vasc Biol.* 2015; 35
44. Di Lorenzo F. *Neuro Endocrinol Lett.* 2015; 36
45. Haldar M, Kohyama M, So AYL, Wumesh K, Wu X, Briseno CG, Satpathy AT, Kretzer NM, Rajasekaran NS, Wang L, Egawa T, Igarashi K, Baltimore D, Murphy TL, Murphy KM. *Biol Trace Elem Res.* 2015; 6
46. Walling C, Goosen A. *J Am Chem Soc.* 1973; 95:2987–91.
47. Khan, Fa; Fisher, Ma; Khakoo, Ra. *Int J Infect Dis.* 2007; 11:482–487. [PubMed: 17600748]
48. Kim EY, Koh JY, Kim YH, Sohn S, Joe E, Gwag BJ. *Eur J Neurosci.* 1999; 11:327–334. [PubMed: 9987035]
49. Dineley KE, Richards LL, Votyakova TV, Reynolds IJ. *Mitochondrion.* 2005; 5:55–65. [PubMed: 16060292]
50. Clausen A, McClanahan T, Ji SG, Weiss JH. *PLoS One.* 2013; 8:1–12.
51. Fosmire G. *Am J Clin Nutr.* 1990; 51:225–227. [PubMed: 2407097]
52. Hooper P, Visconti L, Garry P, Johnson G. *J Am Med Assoc.* 1980; 244:1960–1961.
53. Hood MI, Skaar EP. *Nat Rev Microbiol.* 2012; 10:525–537. [PubMed: 22796883]
54. Kr el A, Maret W. *J Biol Inorg Chem.* 2006; 11:1049–62. [PubMed: 16924557]
55. Magneson GR, Puvathingal JM, Ray WJ. *J Biol Chem.* 1987; 262:11140–11148. [PubMed: 2956262]

56. Lewis JP. *Periodontology*. 2010; 52:94–116.
57. Zalewski PD, Truong-Tran AQ, Grosser D, Jayaram L, Murgia C, Ruffin RE. *Pharmacol Ther*. 2005; 105:127–49. [PubMed: 15670623]
58. Cassat JE, Skaar EP. *Cell Host Microbe*. 2014; 13:509–519. [PubMed: 23684303]
59. Shetty, PS. *Nutrition, Immunity and Infection*. CABI; Oxfordshire, UK: 2010. p. 88-95.
60. Ganz T. *Blood*. 2011; 117:4425–4433. [PubMed: 21346250]
61. Cousins R, Dunn M, Leinart A, Yedinak K, DiSilvestro R. *Am J Pathol*. 1986; 251:688–694.
62. Gaetke LM, McClain CJ, Talwalkar RT, Shedlofsky SI. *Am J Physiol*. 1997; 272:E952–6. [PubMed: 9227437]
63. Gabay C, Kushner I. *N Engl J Med*. 1999; 340:448–454. [PubMed: 9971870]
64. Guo L, Lichten LA, Ryu MS, Liuzzi JP, Wang F, Cousins RJ. *Proc Natl Acad Sci U S A*. 2010; 107:2818–23. [PubMed: 20133611]
65. Gkouvatso K, Papanikolaou G, Pantopoulos K. *Biochim Biophys Acta*. 2012; 1820:188–202. [PubMed: 22085723]
66. Barber MF, Elde NC. *Science*. 2014; 12:1362–6. [PubMed: 25504720]
67. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. *Mol Cell*. 2002; 10:1033–1043. [PubMed: 12453412]
68. Steigedal M, Marstad A, Haug M, Damas JK, Strong RK, Roberts PL, Himpel SD, Stapleton A, Hooton TM, Mobley HLT, Hawn TR, Flo TH. *J Immunol*. 2014; 193:6081–6089. [PubMed: 25398327]
69. Miethke M, Marahiel MA. *Microbiol Mol Biol Rev*. 2007; 71:413–451. [PubMed: 17804665]
70. Holden VI, Lenio S, Kuick R, Ramakrishnan SK, Shah YM, Bachman MA. *Infect Immun*. 2014; 82:3826–3836. [PubMed: 24980968]
71. Kehl-Fie TE, Skaar EP. *Curr Opin Chem Biol*. 2010; 14:218–24. [PubMed: 20015678]
72. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo BM, Dunman PM, Gerads R, Caprioli M, Nacken W, Chazin WJ, Skaar EP, Torres VJ, Anderson KL, Dattilo BM, Dunman PM, Gerads R. *Science*. 2008; 319:962–965. [PubMed: 18276893]
73. Sohnle PG, Collins-lech C, Wiessner J. *J Infect Dis*. 1991; 163:187–192. [PubMed: 1984467]
74. Nairz M, Schroll A, Demetz E, Tancevski I, Theurl I, Weiss G. *Immunobiology*. 2014; 220:280–294. [PubMed: 25240631]
75. Cherayil BJ. *Arch Immunol Ther Exp*. 2011; 58:407–15.
76. Cherayil B. *Immunol Res*. 2011; 50:1–9. [PubMed: 21161695]
77. Dennis MK, Field AS, Burai R, Ramesh C, Whitney K, Bologna CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar La, Hathaway HJ, Arterburn JB, Prossnitz ER. *Cell*. 2014; 156:1223–34. [PubMed: 24630724]
78. Noinaj N, Buchanan SK, Cornelissen CN. *Mol Microbiol*. 2013; 86:246–257. [PubMed: 22957710]
79. Ma L, Kaserer W, Annamalai R, Scott DC, Jin B, Jiang X, Xiao Q, Maymani H, Massis LM, Ferreira LCS, Newton SMC, Klebba PE. *J Biol Chem*. 2007; 282:397–406. [PubMed: 17056600]
80. Parker Siburt CJ, Mietzner TA, Crumbliss AL. *Biochim Biophys Acta - Gen Subj*. 2012; 1820:379–392.
81. Biswas GD, Sparling PF. *Infect Immun*. 1995; 63:2958–2967. [PubMed: 7622218]
82. Prinz T, Meyer M, Pettersson A, Tommassen J. *J Bacteriol*. 1999; 181:4417–4419. [PubMed: 10400602]
83. Gray-Owen SD, Schryvers AB. *Infect Immun*. 1995; 63:3809–3815. [PubMed: 7558284]
84. Boradia VM, Malhotra H, Thakkar JS, Tillu VA, Vuppala B, Patil P, Sheokand N, Sharma P, Chauhan AS, Raje M, Raje CI. *Nat Commun*. 2014; 5:4730. [PubMed: 25163484]
85. Rooijackers SHM, Rasmussen SL, McGillivray SM, Bartnikas TB, Mason AB, Friedlander AM, Nizet V. *J Biol Chem*. 2010; 285:27609–27613. [PubMed: 20615872]
86. Contreras H, Chim N, Credali A, Goulding CW. *Curr Opin Chem Biol*. 2014; 19:34–41. [PubMed: 24780277]

87. Cescau S, Cwerman H, Létoffé S, Delepelaire P, Wandersman C, Biville F. *Biometals*. 2007; 20:603–13. [PubMed: 17268821]
88. Ghigo J, Létoffé S, Wandersman C. *J Bacteriol*. 1997; 179:3572–3579. [PubMed: 9171402]
89. Sheldon JR, Heinrichs DE. *FEMS Microbiol Rev*. 2015; 39:592–630. [PubMed: 25862688]
90. Ekworomadu MT, Poor CB, Owens CP, Balderas Ma, Fabian M, Olson JS, Murphy F, Balkabasi E, Honsa ES, He C, Goulding CW, Maresso AW. *PLoS Pathog*. 2012; 8
91. Spirig T, Malmirchegini GR, Zhang J, Robson SA, Sjodt M, Liu M, Kumar KK, Dickson CF, Gell Da, Lei B, Loo JA, Clubb RT. *J Biol Chem*. 2013; 288:1065–1078. [PubMed: 23132864]
92. Maresso AW, Chapa TJ, Schneewind O. *J Bacteriol*. 2006; 188:8145–8152. [PubMed: 17012401]
93. Balderas MA, Nobles CL, Honsa ES, Maresso AW. *J Bacteriol*. 2012; 194:5513–21. [PubMed: 22865843]
94. Honsa ES, Maresso AW. *BioMetals*. 2011; 24:533–545. [PubMed: 21258843]
95. Maresso AW, Garufi G, Schneewind O. *PLoS Pathog*. 2008; 4:e1000132. [PubMed: 18725935]
96. Honsa ES, Maresso AW, Highlander SK. *PLoS One*. 2014; 9:e104794. [PubMed: 25153520]
97. Malmirchegini GR, Sjodt M, Shnitkind S, Sawaya MR, Rosinski J, Newton SM, Klebba PE, Clubb RT. *J Biol Chem*. 2014; 289:34886–34899. [PubMed: 25315777]
98. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, Mcneely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS. *Infect Immun*. 2006; 74:2215–2223. [PubMed: 16552052]
99. Joshi A, Pancari G, Cope L, Bowman EP, Cua D, Proctor RA, McNeely T. *Hum Vaccin Immunother*. 2012; 8:336–346. [PubMed: 22327491]
100. Saito H. *Nagoya J Med Sci*. 2014; 76:235–54. [PubMed: 25741033]
101. Dehner C, Morales-Soto N, Behera R, ShROUT J, Theil E, Maurice P, Dubois J. *J Biol Inorg Chem*. 2013; 18:371–81. [PubMed: 23417538]
102. Whitby PW, VanWagoner TM, Springer JM, Morton DJ, Seale TW, Stull TL. *J Med Microbiol*. 2006; 55:661–668. [PubMed: 16687582]
103. Segond D, Abi Khalil E, Buisson C, Daou N, Kallassy M, Lereclus D, Arosio P, Bou-Abdallah F, Nielsen Le Roux C. *PLoS Pathog*. 2014; 10
104. Müller SI, Valdebenito M, Hantke K. *BioMetals*. 2009; 22:691–695. [PubMed: 19214756]
105. Raffatellu M, George MD, Akiyama Y, Hornsby MJ, Nuccio SP, Paixao TA, Butler BP, Chu H, Santos RL, Berger T, Mak TW, Tsoilis RM, Bevins CL, Solnick JV, Dandekar S, Bäumlér AJ. *Cell Host Microbe*. 2009; 5:476–486. [PubMed: 19454351]
106. Watts RE, Totsika M, Challinor VL, Mabbett AN, Ulett GC, De Voss JJ, Schembri Ma. *Infect Immun*. 2012; 80:333–344. [PubMed: 21930757]
107. Heesemann J, Hantke K, Vocke T, Saken E, Rakin A, Stojiljkovic I, Berner R. *Mol Microbiol*. 1993; 8:397–408. [PubMed: 8316088]
108. Brumbaugh AR, Smith SN, Subashchandrabose S, Himpsl SD, Hazen TH, Rasko Da, Mobley HLT. *Infect Immun*. 2015; 83:1443–1450. [PubMed: 25624354]
109. Lawlor MS, O'Connor C, Miller VL. *Infect Immun*. 2007; 75:1463–1472. [PubMed: 17220312]
110. Pradel E, Lemaître N, Merchez M, Ricard I, Reboul A, Dewitte A, Sebbane F. *PLoS Pathog*. 2014; 10
111. Reeves SA, Gonzales EG, Payne SM. *Infect Immun*. 2003; 71:1919–1928. [PubMed: 12654809]
112. Payne SM, Wyckoff EE, Murphy ER, Oglesby AG, Boulette ML, Davies NML. *BioMetals*. 2006; 19:173–180. [PubMed: 16718602]
113. Gao Q, Wang X, Xu Y, Xu Y, Ling J, Zhang D, Gao S, Liu X. *BMC Microbiol*. 2012; 12:143. [PubMed: 22817680]
114. Nassif X, Sansonetti PJ. *Infect Immun*. 1986; 54:603–608. [PubMed: 2946641]
115. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, S Akashi-takamura, Miyake K, Zhang J, Lee WP, Forsberg LS, Carlson RW, Dixit VM. *Science*. 2013; 341:1246–1249. [PubMed: 23887873]

116. O'Riordan M, Portnoy Da. Trends Microbiol. 2002; 10:361–364. [PubMed: 12160633]
117. Payne SM. Mol Microbiol. 1989; 3:1301–6. [PubMed: 2677608]
118. Pan X, Tamilselvam B, Hansen EJ, Daefler S. BMC Microbiol. 2010; 10:64. [PubMed: 20184753]
119. Zughaier SM, Kandler JL, Shafer WM. PLoS One. 2014; 9
120. Corbett D, Wang J, Schuler S, Lopez-Castejon G, Glenn S, Brough D, Andrew PW, Cavet JS, Roberts IS. Infect Immun. 2012; 80:14–21. [PubMed: 22025520]
121. Ammendola S, Pasquali P, Pistoia C, Petrucci P, Petrarca P, Rotilio G, Battistoni A. Infect Immun. 2007; 75:5867–76. [PubMed: 17923515]
122. Desrosiers DC, Bearden SW, Mier I, Abney J, Paulley JT, Fetherston JD, Salazar JC, Radolf JD, Perry RD. Infect Immun. 2010; 78:5163–77. [PubMed: 20855510]
123. Patzer S, Hantke K. Mol Microbiol. 1998; 28:1199–1210. [PubMed: 9680209]
124. Hantke K. Biometals. 2001; 14:239–249. [PubMed: 11831459]
125. Ma Z, Jacobsen F, Giedroc D. Chem Rev. 2009; 109:4644–4681. [PubMed: 19788177]
126. Sabri M, Houle S, Dozois CM. Infect Immun. 2009; 77:1155–64. [PubMed: 19103764]
127. Weston BF, Brenot A, Caparon MG. Infect Immun. 2009; 77:2840–8. [PubMed: 19398546]
128. Kim S, Watanabe K, Shirahata T, Watarai M. J Vet Med Sci. 2004; 66:1059–1063. [PubMed: 15472468]
129. Yang X, Becker T, Walters N, Pascual DW. Infect Immun. 2006; 74:3874–9. [PubMed: 16790759]
130. Botella H, Peyron P, Levillain F, Poincloux R, Poquet Y, Brandli I, Wang C, Tailleux L, Tilleul S, Charrière GM, Waddell SJ, Foti M, Lugo-Villarino G, Gao Q, Maridonneau-Parini I, Butcher PD, Castagnoli PR, Gicquel B, de Chastellier C, Neyrolles O. Cell Host Microbe. 2011; 10:248–59. [PubMed: 21925112]
131. Stork M, Grijpstra J, Bos MP, C Mañas Torres, Devos N, Poolman JT, Chazin WJ, Tommassen J. PLoS Pathog. 2013; 9:e1003733. [PubMed: 24204275]
132. Carpenter BM, Whitmire JM, Merrell DS. Infect Immun. 2009; 77:2590–2601. [PubMed: 19364842]
133. Troxell B, Hassan HM. Front Cell Infect Microbiol. 2013; 3:59. [PubMed: 24106689]
134. Porcheron G, Habib R, Houle S, Caza M, Lepine F, Daigle F, Masse E, Dozois CM. Infect Immun. 2014; 82:5056–5068. [PubMed: 25245805]
135. Murphy ER, Payne SM. Infect Immun. 2007; 75:3470–3477. [PubMed: 17438026]
136. Reinhart AA, Powell DA, Nguyen AT, O'Neill M, Djapgne L, Wilks A, Ernst RK, Oglesby-Sherrouse AG. Infect Immun. 2015; 83:863–875. [PubMed: 25510881]
137. Lewin AC, Doughty Pa, Flegg L, Moore GR, Spiro S. Microbiology. 2002; 148:2449–2456. [PubMed: 12177338]
138. Pecqueur L, D'Autréaux B, Dupuy J, Nicolet Y, Jacquamet L, Brutscher B, Michaud-Soret I, Bersch B. J Biol Chem. 2006; 281:21286–21295. [PubMed: 16690618]
139. Outten CE, Halloran TVO. Science (80-). 2001; 292:2488–2492.
140. Hantke K. Curr Opin Microbiol. 2005; 8:196–202. [PubMed: 15802252]
141. Grass G, Franke S, Taudte N, Nies DH, Kucharski LM, Maguire ME, Rensing C. J Bacteriol. 2005; 187:1604–1611. [PubMed: 15716430]
142. Gonzales T, Robert-Baudouy J. FEMS Microbiol Rev. 1996; 18:319–344. [PubMed: 8703509]
143. Kaman WE, Hays JP, Endtz HP, Bikker FJ. Eur J Clin Microbiol Infect Dis. 2014; 33:1081–7. [PubMed: 24535571]
144. Raju RM, Goldberg AL, Rubin EJ. Nat Rev Drug Discov. 2012; 11:777–89. [PubMed: 23023677]
145. Vallee BL, Auld DS. Proc Natl Acad Sci U S A. 1990; 87:220–224. [PubMed: 2104979]
146. Miyoshi S, Shinoda S. Microbes Infect. 2000; 2:91–8. [PubMed: 10717546]
147. Wu JW, Chen XL. Appl Microbiol Biotechnol. 2011; 92:253–62. [PubMed: 21845384]
148. Chang AK, Kim HY, Park JE, Acharya P, Park I, Yoon SM, You HJ, Hahm K, Park JK, Lee JS. J Bacteriol. 2005; 187:6909–6916. [PubMed: 16199560]

149. Chung M-C, Popova TG, Millis Ba, Mukherjee DV, Zhou W, Liotta La, Petricoin EF, Chandhoke V, Bailey C, Popov SG. *J Biol Chem*. 2006; 281:31408–18. [PubMed: 16926147]
150. Kooi C, Subsin B, Chen R, Pohorelic B, Sokol Pa. *Infect Immun*. 2006; 74:4083–93. [PubMed: 16790782]
151. Harrington DJ. *Infect Immun*. 1996; 64:1885–1891. [PubMed: 8675283]
152. Kooi C, Corbett CR, Sokol PA. *J Bacteriol*. 2005; 187:4421–4429. [PubMed: 15968051]
153. Azghani A, Gray LD, Johnson AR. *Infect Immun*. 1993; 61:0–5.
154. Wu Z, Nybom P, Magnusson K. *Cell Microbiol*. 2000; 2:11–17. [PubMed: 11207559]
155. Mukherjee DV, Tonry JH, Kim KS, Ramarao N, Popova TG, Bailey C, Popov S, Chung MC. *PLoS One*. 2011; 6
156. Plaut AG, Genco RJ, Tomasi TB. *J Immunol*. 1974; 113
157. Molla A, Matsumoto K, Oyamada I, Katsuki T, Maeda H. *Infect Immun*. 1986; 53:522–529. [PubMed: 2427450]
158. Loomes LM, Kerr MA, Senior BW. *J Med Microbiol*. 1993; 39:225–232. [PubMed: 8366522]
159. Brezski RJ, Jordan RE. *MAbs*. 2010; 2:212–20. [PubMed: 20400859]
160. Kehl-Fie T, Chitayat S, Hood MI, Dama S, Restrepo N, Garcia C, Munro KA, Chazin WJ, Skaar EP. *Cell Host Microbe*. 2012; 10:158–164. [PubMed: 21843872]
161. Nisapakultorn K, Ross KF. *Infect Immun*. 2001; 69:4242–4247. [PubMed: 11401960]
162. Warfel JM, Steele AD, Agnillo FD. *Am J Pathol*. 2005; 166:1871–1881. [PubMed: 15920171]
163. Kastrop CJ, Boedicker JQ, Pomerantsev AP, Moayeri M, Pompano RR, Kline TR, Sylvestre P, Shen F, Leppla H, Tang W, Ismagilov RF. *Nat Chem Biol*. 2008; 4:742–750. [PubMed: 19031531]
164. Mintz CS, Miller RD, Gutsell NS, Malek T. *Infect Immun*. 1993; 61:3416–3421. [PubMed: 8335371]
165. Vollmer P, Walev I, Rose-john S, Bhakdi S. *Infect Immun*. 1996; 64:3646–3651. [PubMed: 8751912]
166. Abu Kwaik Y, Bumann D. *Cell Microbiol*. 2013; 15:882–90. [PubMed: 23490329]
167. Price C, Al Quadan T, Santic M, Rosenshine I, Abu Kwaik Y. *Science (80-)*. 2011; 334
168. Carlsson J, Hogling JD, Sundqvist G. *J Med Microbiol*. 1984; 0:39–46. [PubMed: 6748039]
169. Otto BR, van Dooren SJ, Nuijens JH, Luirink J, Oudega B. *J Exp Med*. 1998; 188:1091–1103. [PubMed: 9743528]
170. Guan SM, Nagata H, Shizukuishi S, Wu JZ. *Anaerobe*. 2006; 12:279–82. [PubMed: 17081784]
171. Park BR, Zielke Ra, Wierzbicki IH, Mitchell KC, Withey JH, Sikora AE. *J Bacteriol*. 2015; 197:1051–64. [PubMed: 25561716]
172. Terwilliger A, Swick MC, Pflughoeft KJ, Pomerantsev A, Lyons CR, Koehler TM, Maresso A. *J Bacteriol*. 2015; 197:2400–2411. [PubMed: 25962917]
173. Walsh TR, Toleman MA, Poirel L, Nordmann P. *Clin Microbiol Rev*. 2005; 18:306–325. [PubMed: 15831827]
174. Palzkill T. *Ann N Y Acad Sci*. 2013; 1277:91–104. [PubMed: 23163348]
175. Tong Y, Guo M. *Arch Biochem Biophys*. 2009; 481:1–15. [PubMed: 18977196]
176. Fuursted K, Schøler L, Hansen F, Dam K, Bojer MS, Hammerum AM, Dagnæs-Hansen F, Olsen A, Jasemian Y, Struve C. *Microbes Infect*. 2012; 14:155–8. [PubMed: 21925284]
177. Gayathri D, Eramma NK, Devaraja TN. *Int J Biol Med Res*. 2012; 3:1870–1874.
178. Lopetuso LR, Scaldaferrri F, Franceschi F, Gasbarrini A. *Best Pr Res Clin Gastroenterol*. 2014; 28:995–1002.
179. Martín R, Miquel S, Ulmer J, Kechaou N, Langella P, Bermúdez-Humarán LG. *Microb Cell Fact*. 2013; 12:71. [PubMed: 23876056]
180. Neilands JB. *Horiz Biochem Biophys*. 1978; 5:65–98. [PubMed: 150390]
181. Braun V, Mahren S, Ogierman M. *Curr Opin Microbiol*. 2003; 6:173–180. [PubMed: 12732308]
182. Eisner BH, Asplin JR, Goldfarb DS, Ahmad A, Stoller ML. *J Urol*. 2010; 183:2419–2423. [PubMed: 20403610]

183. Cartron ML, Maddocks S, Gillingham P, Craven CJ, Andrews SC. *BioMetals*. 2006; 19:143–157. [PubMed: 16718600]
184. Flint HJ, Scott KP, Louis P, Duncan SH. *Nat Rev Gastroenterol Hepatol*. 2012; 9:577–589. [PubMed: 22945443]
185. Rocha, ER.; Smith, CJ. Iron uptake and homeostasis in microorganisms. Andrews, SC.; Cornelis, P., editors. Caister Academic Press; Norwich, UK.: 2010. p. 155-165.
186. Otto BR, Verweij-van Vught AMJJ, van Doorn J, Maclaren DM. *Microb Pathog*. 1988; 4:279–287. [PubMed: 3200164]
187. Neilands, JB. Biochemistry of metal micronutrients in the Rhizosphere. Manthey, J.; Crowley, DE.; Luster, DG., editors. CRC Press; Boca Raton, FL: 1994. p. 20-21.
188. Otto BR, Sparrius M, Verweij-van Vught AMJJ, MacLaren DM. *Infect Immun*. 1990; 58:3954–3958. [PubMed: 2254022]
189. Otto BR, Kusters JG, Luirink J, De Graaf FK, Oudega B. *Infect Immun*. 1996; 64:4345–4350. [PubMed: 8926109]
190. Manfredi P, Lauber F, Renzi F, Hack K, Hess E, Cornelis GR. *Infect Immun*. 2015; 83:300–310. [PubMed: 25368114]
191. Peters BM, Jabra-Rizk MA, O'May Ga, William Costerton J, Shirtliff ME. *Clin Microbiol Rev*. 2012; 25:193–213. [PubMed: 22232376]
192. Nair N, Biswas R, Götz F, Biswas L. *Infect Immun*. 2014; 82:2162–2169. [PubMed: 24643542]
193. Mashburn LM, Jett AM, Akins DR, Whiteley M. *J Bacteriol*. 2005; 187:554–566. [PubMed: 15629927]
194. Hammer ND, Cassat JE, Noto MJ, Lojek LJ, Chadha AD, Schmitz JE, Creech CB, Skaar EP. *Cell Host Microbe*. 2014; 16:531–537. [PubMed: 25299336]
195. Ballouche M, Cornelis P, Baysse C. *Recent Pat Antiinfect Drug Discov*. 2009; 4:190–205. [PubMed: 19594436]
196. Mislin GL, Schalk IJ. *Metallomics*. 2014; 6:408–20. [PubMed: 24481292]
197. Thompson MG, Corey BW, Si Y, Craft DW, Zurawski DV. *Antimicrob Agents Chemother*. 2012; 56:5419–5421. [PubMed: 22850524]
198. Fernandes SS, Nunes A, Gomes AR, de Castro B, Hider RC, Rangel M, Appelberg R, Gomes MS. *Microbes Infect*. 2010; 12:287–294. [PubMed: 20097303]
199. Visca P, Bonchi C, Minandri F, Frangipani E, Imperi F. *Antimicrob Agents Chemother*. 2013; 57:2432–2433. [PubMed: 23580579]
200. Gentile V, Frangipani E, Bonchi C, Minandri F, Runci F, Visca P. *Pathogens*. 2014; 3:704–719. [PubMed: 25438019]
201. Banin E, Brady KM, Greenberg EP. *Appl Environ Microbiol*. 2006; 72:2064–2069. [PubMed: 16517655]
202. [Apr 18, 2015] Publichealthwatch. <https://publichealthwatch.wordpress.com/2014/09/10/novel-antibiotic-may-offer-new-approach-to-treating-drug-resistant-superbugs/>
203. Lane DJR, Merlot AM, Huang MLH, Bae DH, Jansson PJ, Sahni S, Kalinowski DS, Richardson DR. *Biochim Biophys Acta*. 2015; 1853:1130–1144. [PubMed: 25661197]
204. Correnti C, Strong RK. *J Biol Chem*. 2012; 287:13524–31. [PubMed: 22389496]
205. Miethke M. *Metallomics*. 2013; 5:15–28. [PubMed: 23192658]
206. Schalk IJ, Guillon L. *Amino Acids*. 2013; 44:1267–77. [PubMed: 23443998]
207. Bertrand, S. [Aug 11, 2015] http://bertrandsamuel.free.fr/siderophore_base/siderophores.php
208. Hider R, Kong X. *Nat Prod Rep*. 2010; 27:637–57. [PubMed: 20376388]
209. Crumbliss AL, Harrington JM. *Adv Inorg Chem*. 2009; 61:179–250.
210. Hederstedt L. *Biochim Biophys Acta - Bioenerg*. 2012; 1817:920–927.
211. Roche B, Aussel L, Ezraty B, Mandin P, Py B, Barras F. *Biochim Biophys Acta*. 2013; 1827:923–937. [PubMed: 23660107]
212. Isani G, Carpenè E. *Biomolecules*. 2014; 4:435–57. [PubMed: 24970224]
213. Jackson BC, Nebert DW, Vasiliou V. 2010; 4:194–201.

214. Edwards DR, Handsley MM, Pennington CJ. *Mol Aspects Med.* 2008; 29:258–89. [PubMed: 18762209]
215. Sterchi EE, Socker W, Bond JS. *Mol Aspects Med.* 2010; 29:309–328. [PubMed: 18783725]
216. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. *Curr Mol Med.* 2013; 13:24–57. [PubMed: 22834835]
217. Laity JH, Lee BM, Wright PE. *Curr Opin Struct Biol.* 2001; 11:39–46. [PubMed: 11179890]
218. Coleman JE. *Annu Rev Biochem.* 1992; 61:897–946. [PubMed: 1497326]
219. Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. *Mol Aspects Med.* 2012; 33:209–90. [PubMed: 22230555]
220. Rehman AA, Ahsan H, Khan FH. *J Cell Physiol.* 2013; 228:1665–75. [PubMed: 23086799]
221. Kallifidas D, Pascoe B, Owen Ga, Strain-Damerell CM, Hong H-J, Paget MSB. *J Bacteriol.* 2010; 192:608–11. [PubMed: 19915027]
222. Hase CC, Finkelstein RA. *Microbiol Rev.* 1993; 57:823–837. [PubMed: 8302217]




Figure 1. Bacterial iron uptake in the host

Under normal conditions, commensal bacteria of the GI tract use siderophore-based iron uptake systems to obtain iron. Upon infection, the host uses nutritional immunity to restrict bacterial access to essential nutrients including iron (top panel). Host iron limitation includes hepcidin- mediated reduction of circulatory iron and/or the production of NGAL to prevent siderophores from chelating free iron. Additionally, iron is kept unavailable for bacteria by being bound to heme or proteins such as transferrin or ferritin. Bacterial pathogens employ diverse strategies to counter nutritional immunity (bottom panel), including the utilization of

transferrin/lactoferrin, heme/heme-containing proteins, iron storage proteins such as ferritin, blocking the host from recognizing their siderophores, utilizing other species siderophores, and even invading into the cytoplasm of host cells.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. The role of zinc in bacterial pathogenesis

A. Bacterial pathogens encounter higher concentrations of zinc at epithelial surfaces, where lysed cells release metallothioneins that liberate zinc upon oxidative stress. To combat Zn^{2+} toxicity, bacteria employ efflux transporters like RND, ZnT and Pit. ZUR proteins are bound to bacterial DNA and prevent transcription of zinc uptake mechanisms. Metalloproteases cleave mucins, glycoproteins, and tight cell junctions to allow bacteria to translocate into other tissues. **B.** At sites of infection and translocation, the host can reduce available zinc by secreting the zinc chelator calprotectin. Once in zinc deficient environments, bacterial ZUR proteins relieve transcriptional repression and zinc uptake mechanisms are expressed, such as the Znu ABC transporter. Here, metalloproteases can cleave collagen, cytokine receptors, cytokines and immunoglobulins to further disrupt tissues and interfere with immune signaling. **C.** When present in the bloodstream, host α -2-macroglobulin can inactivate metalloproteases via entrapment. However, metalloproteases can cleave fibrinogen, prothrombin, and factor X to disrupt the clotting cascade and permit further dissemination.

Table 1

Host and bacterial factors involved in iron and zinc exploitation.

Iron	Protein Type	Localization	Function	Reference
Host sources of iron	Heme containing proteins	Cell membranes, Cytoplasm	Transport electrons and oxygen during respiration	203
	Transferrin	Blood, interstitial fluid	Sequester iron in blood and interstitial fluid	65,203
	Lactoferrin	Secretory fluids	Sequester iron in secretory fluids	58
	Ferritin	Cytoplasm	Store iron to balance intracellular iron concentrations	100
	labile iron pool	Cytoplasm	Buffer intracellular iron concentrations	204
Iron acquisition systems	Membrane receptors	Cell membranes	Actively transport iron from the environments	205
	ABC transporters	Cell membranes	Actively transport iron from the environments	206
	Siderophores	Secreted	Chelates iron with high affinity	207–209
Utilization of acquired iron	Heme biosynthesis	Cytoplasm	Transport electrons and bind diatomic gases in respiration, defend oxidative stress	210
	Iron-sulfur protein biosynthesis	Cytoplasm	Synthesize dNTPs, produce energy, and defend against oxidative stress	211
Zinc	Protein Type	Localization	Function	Reference
Host sources of zinc	Metallothioneins	Cytoplasm	Zinc buffering, suppress inflammatory cytokine secretion	32,212
	Zincosomes	Cytoplasm	Zinc storage and buffering	33
	Metalloproteinases	Cytoplasm, membrane, and secreted	Degrade extracellular matrix, direct cellular differentiation and tissue morphogenesis	213–215
	Calprotectin	Cytoplasm – secreted by neutrophils	Chelate zinc and manganese at site of infection	71
	S100 proteins	Cytoplasm – secreted by neutrophils	Regulate cell proliferation and differentiation. Chelate metals at site of infection	216
	Zinc fingers	Cytoplasm/nucleus	Transcription factors, nucleases, polymerases, ribosomes	217,218
	Serum albumin	Blood, interstitial fluid	Maintain osmotic pressure, carry metabolites	219
	α -2-macroglobulin	Blood	Inhibits bacterial proteases via entrapment	220
Zinc acquisition systems	ZIP (Zrt-Irt-like protein)	Cell Membrane	Diffusion	140
	Znu (ABC)	Cell Membrane	Active Transport	13
	Zincophores	Secreted	Putatively bind zinc for transport	221

Iron	Protein Type	Localization	Function	Reference
	Calprotectin Binding Protein	Secreted	Binds calprotectin for transport	131
Utilization of zinc during pathogenesis	Metalloproteases	Secreted	Compromise epithelial and endothelial barriers, interfere with clotting cascade, cleave immune proteins to evade clearance.	146,149,222

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript